NCT05117489View on ClinicalTrials.gov

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

January 29, 2024

Study Completion Date

January 29, 2024

Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
DRUG

Miricorilant 150 mg

Miricorilant 150 mg for oral dosing

DRUG

Miricorilant 100 mg

Miricorilant 100 mg for oral dosing

DRUG

Miricorilant 50 mg

Miricorilant 50 mg for oral dosing

DRUG

Miricorilant 10 mg

Miricorilant 10 mg for oral dosing.

Trial Locations (9)

77079

Site 305, Houston

78229

Site 212, San Antonio

78539

Site 213, Edinburg

78757

Site 211, Austin

85224

Site 207, Chandler

85712

Site 209, Tucson

91402

Site 214, Panorama City

92704

Site 233, Santa Ana

98105

226, Seattle

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY